Skip to main content
. 2019 Dec 30;117(1):541–551. doi: 10.1073/pnas.1902145116

Fig. 1.

Fig. 1.

Therapeutic efficacy of Ang2/VEGFA blockade in combination with agonistic CD40 antibodies. (A) Tumor volume and (B) Kaplan−Meier survival plot of MC38 tumors inoculated s.c. in C57BL/6 mice. Mice were treated as indicated. Anti-CD40 (1C10) or control muIgG (both at 5 mg/kg) were administered i.p. on days 18, 20, 23, and 25, whereas anti-VEGFA and anti-Ang2 (both at 10 mg/kg) were administered i.p. on days 18 and 23 postcell inoculation. Pooled data of 3 independent experiments are shown. The number of tumor-free mice out of the total number of mice, assessed at day 100 posttumor challenge, is indicated in each graph in A. (C) Relative necrotic area in MC38 tumors treated as indicated, measured in the largest tumor section. Each dot indicates one tumor. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA with Tukey’s correction for multiple comparisons. (D) Representative images of tumor sections stained with hematoxylin/eosin. (Scale bar, 1,000 μm.) The number of mice employed in each experiment is reported in Dataset S2.